Sign in

Private company

Kaya Holdings, Inc.

Kaya Holdings, Inc. is an American pharmaceutical preparations company based in Fort Lauderdale.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersFort Lauderdale, Florida1
  • Incorporated inDE2
  • Business address915 Middle River Drive, Suite 316, Fort Lauderdale, Fl 333042
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

The Company currently has one retail cannabis license in Oregon and two medical marijuana production and processing licenses in Greece.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-5.1%Gross margin4
-28343.5%Operating margin4
-29168.2%Net margin4
-96.4%Revenue growth, 20244
-$858.0KFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue100¢$7.5K

Out of $7.1K in revenue.4 The company lost money this year.

Financial statements

Revenue56784$7.1K in 2024−99% since 2019
0$500.0K$1.0M$1.5M2019: $1.0M$1.0M20192020: $1.0M$1.0M2020+2%2021: $889.9K$889.9K2021−14%2022: $685.4K$685.4K2022−23%2023: $196.3K$196.3K2023−71%2024: $7.1K$7.1K2024−96%
Gross profit956784-$366 in 2024
-$200.0K0$200.0K$400.0K$600.0K$800.0K2018: $642.5K$642.5K20182019: $604.0K$604.0K2019−6%2020: $718.9K$718.9K2020+19%2021: $610.6K$610.6K2021−15%2022: $460.3K$460.3K2022−25%2023: $114.9K$114.9K2023−75%2024: -$366-$3662024
Operating income956784-$2.0M in 2024−30% since 2018
-$3.0M-$2.0M-$1.0M02018: -$2.9M-$2.9M20182019: -$2.3M-$2.3M2019−21%2020: -$1.8M-$1.8M2020−19%2021: -$1.4M-$1.4M2021−22%2022: -$1.7M-$1.7M2022+20%2023: -$1.0M-$1.0M2023−40%2024: -$2.0M-$2.0M2024+98%
Net income956784-$2.1M in 2024
-$20.0M-$10.0M0$10.0M2018: $4.5M$4.5M20182019: $7.5M$7.5M2019+66%2020: -$12.3M-$12.3M20202021: $9.7M$9.7M20212022: -$3.6M-$3.6M20222023: $1.6M$1.6M20232024: -$2.1M-$2.1M2024
Fiscal year2018201920202021202220232024
Revenue$1.0M5$1.0M6$889.9K7$685.4K8$196.3K8$7.1K4
Cost of revenue$494.1K9$410.2K5$310.7K6$279.3K7$225.1K8$81.3K8$7.5K4
Gross profit$642.5K9$604.0K5$718.9K6$610.6K7$460.3K8$114.9K8-$3664
Operating expenses$2.0M7$2.2M8$1.0M4$2.0M4
Operating income-$2.9M9-$2.3M5-$1.8M6-$1.4M7-$1.7M8-$1.0M4-$2.0M4
Interest$541.0K9$579.7K5$602.8K6$635.8K6
Income tax$012$93.9K13$23.3K13$23.3K8
Net income$4.5M9$7.5M5-$12.3M6$9.7M7-$3.6M8$1.6M4-$2.1M4
Earnings per share$0.039$0.005-$1.005$0.074-$0.074
Earnings per share (diluted)$0.019$0.025-$0.925$0.014-$0.074
Shares (weighted, basic)22.2M shares428.4M shares4
Shares (weighted, diluted)203.7M shares4257.7M shares4

Compare Kaya Holdings, Inc. with another company

What it owns

What Kaya Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$17.7K4 Dec 31, 2024$17.7K4 Dec 31, 20230%
Machinery and equipment$55.1K4 Dec 31, 2024$55.1K4 Dec 31, 20230%
Furniture and fixtures$57.0K4 Dec 31, 2024$57.0K4 Dec 31, 20230%
Leasehold improvements$59.4K4 Dec 31, 2024$32.3K4 Dec 31, 2023+84.0%
Property and equipment, before depreciation$241.8K8 Dec 31, 2023$911.2K8 Dec 31, 2022−73.5%
Accumulated depreciation$372.4K4 Dec 31, 2024$216.9K4 Dec 31, 2023+71.7%
Property and equipment, net$46.1K4 Dec 31, 2024$24.9K4 Dec 31, 2023+85.5%
Operating-lease assets (leased space)$52.6K4 Dec 31, 2024$29.9K4 Dec 31, 2023+76.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$29.1K8 Dec 31, 2023$18.3K8 Dec 31, 2022+58.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$21.0K4 Dec 31, 2024$23.7K4 Dec 31, 2023−11.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$904 Dec 31, 2024$9.3K4 Dec 31, 2023−99.0%
Finished goods$904 Dec 31, 2024$9.3K4 Dec 31, 2023−99.0%

Properties, in its own words

The Sacred Mushroom Psychedelic Treatment Center occupies approximately 11,000 square feet of leased space (the entire seventh floor) in the gentrifying Old Chinatown area of downtown Portland, Oregon. provides guests with access to private treatment rooms, group session areas, and activity zones with movement, listening stations, journaling chairs, and art expression for distinctive, effective, and positive psilocybin treatments. The setting and space are designed to deliver the ultimate in safe, comfortable, and relaxing psychedelic treatments.

KAYS also leases a work apartment for Craig Frank and other Company personnel in Portland, Oregon, for visiting personnel who are in Oregon in connection with the Company’s operations in that state.

The rest of Item 2

KAYS currently leases a modest corporate office of less than 1,000 square feet in Fort Lauderdale, Florida for use by Craig Frank, KAYS Chief Executive Officer and other Company personnel. However, in during the first quarter of 2025, the Company closed this office due to the increased amount of time spent in Oregon by our CEO and increased capital needs in other areas of operations.

Item 2 of the 10-K filed Apr 29, 2025.3

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorCraig Frank named Feb 15, 202414
  • DirectorCarrie Schwarz named Feb 15, 202414
  • DirectorMitchell Chupak named Feb 15, 202414

Former names

  • Alternative Fuels Americas, Inc.Nov 23, 2011 to Apr 23, 20152
  • Alternative Fuels America, Inc.Oct 27, 2011 to Jan 9, 20122

Timeline

  1. Nov 28, 20258-K Executive or director change15
  2. Oct 23, 20258-K Change in control; Other events16
  3. Sep 22, 20258-K Other events17
  4. Apr 28, 20258-K Executive or director change18
  5. Aug 26, 20248-K Regulation FD disclosure19
  6. Aug 22, 20248-K Bylaws or fiscal year changed20
  7. Jul 10, 20248-K Other events21
  8. Jun 7, 20248-K Other events22
  9. May 10, 20248-K Regulation FD disclosure23
  10. Nov 29, 20238-K Regulation FD disclosure24
  11. Nov 9, 20238-K Regulation FD disclosure25
  12. Oct 23, 20238-K Other events26

Filings

67 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 20 major events, 1 private raises, 24 other. The latest 20:

  1. Mar 30, 2026NT 10-K EDGAR
  2. Nov 28, 20258-K EDGAR
  3. Nov 20, 202510-Q EDGAR
  4. Nov 13, 2025NT 10-Q EDGAR
  5. Oct 23, 20258-K EDGAR
  6. Sep 22, 20258-K EDGAR
  7. Aug 27, 202510-Q EDGAR
  8. Aug 13, 2025NT 10-Q EDGAR
  9. May 21, 202510-Q EDGAR
  10. May 19, 202510-K/A EDGAR
  11. May 14, 2025NT 10-Q EDGAR
  12. Apr 29, 202510-K EDGAR
  13. Apr 28, 20258-K EDGAR
  14. Mar 31, 2025NT 10-K EDGAR
  15. Dec 16, 2024EFFECT EDGAR
  16. Dec 11, 2024CORRESP EDGAR
  17. Dec 11, 2024S-1/A EDGAR
  18. Dec 9, 2024UPLOAD EDGAR
  19. Dec 5, 2024DEL AM EDGAR
  20. Dec 3, 2024S-1 EDGAR

The 67 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$76.5K 2024–2024
Money received by yearMoney received by year, 2024–2024: $76.5K in all. Private raises (Form D) $76.5K.$0$20K$40K$60K$80K2024 · Private raises (Form D): $76.5K2024
Figures by year
YearPrivate raises (Form D)Total
2024$76.5K$76.5K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jan 23, 2024Raised $76,500 in a private offering of securities14 Form D: $765,000 offered in all Form D

SEC filer profile

How Kaya Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKaya Holdings, Inc.1
  • CIK0001530746
  • Employer ID (EIN)90-08980073
  • Filer statusNon-accelerated filer not an emerging growth company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address915 Middle River Drive, Suite 316, Fort Lauderdale, FL 333041
  • Phone954-53478951
  • Shares outstanding686,441,673 as of Nov 17, 202511
  • Public float$479.3K as of Jun 28, 20243
  • AuditorM&K CPAS, Houston, TX PCAOB ID 23783
  • On EDGAR sinceOct 27, 20111
  • Filings215 in all: 8-K (56), 10-Q (42), NT 10-Q (37), 10-K (13), NT 10-K (11), UPLOAD (10), CORRESP (7), 10-K/A (6)1
    All 21 form types

    10-Q/A (6), S-8 (6), D (4), S-1/A (4), 8-K/A (2), EFFECT (2), NTN 10K (2), S-1 (2), 424B3 (1), D/A (1), DEL AM (1), S-8 POS (1), SP 15D2 (1)

  • Latest filingsAnnual report (10-K) Apr 29, 2025
    Quarterly report (10-Q) Nov 20, 2025
    Latest 8-K (8-K) Nov 28, 2025

Risk factors and legal proceedings

The risks Kaya Holdings, Inc. names in Item 1A of its 10-K filed Apr 29, 2025: 29 risks under these headings, as written.3

  • We have a relatively short operating history in our current business upon which investors can evaluate our future prospects.
  • The Company will require additional financing to become commercially viable.
  • We currently rely on certain key individuals, and the loss of one of these key individuals could have an adverse effect on the Company.
  • KAYS must effectively meet the challenges of managing expanding operations.
  • Marijuana and Psilocybin remains illegal in the United States under federal law.
  • The marketing and market acceptance of marijuana and psilocybin may not be as rapid as KAYS expects.
  • KAYS’s business activities are part of emerging industries.
  • Our business could be affected by changes in governmental regulation.
  • We will likely face significant competition.
  • We have borrowed and may be required to borrow funds in the future.
  • Adverse global economic conditions could have a negative effect on our business, results of operations and financial condition and liquidity.
  • Worldwide economic and social instability could adversely affect our revenue, financial condition, or results of operations.
The other 17 risks
  • Risks Related to our Status as a Public Company
  • Our internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.
  • As a smaller reporting company, we are subject to scaled disclosure requirements that may make it more challenging for investors to analyze our results of operations and financial prospects.
  • The costs of being a public company could result in us being unable to continue as a going concern.
  • Risks Related to our Common Stock
  • The market for the KAYS Shares is extremely limited and sporadic
  • KAYS’s common stock is a penny stock. Trading of KAYS’s common stock may be restricted by the penny stock regulations adopted by the Securities and Exchange Commission (the “SEC”) and FINRA’s sales practice requirements, which may limit a stockholder’s ability to buy and sell our common stock.
  • The market for penny stocks has experienced numerous frauds and abuses that could adversely impact KAYS’s common stock.
  • FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our common stock.
  • The price of our common stock may become volatile, which could lead to losses by investors and costly securities litigation.
  • If securities analysts do not initiate coverage or continue to cover our common stock or publish unfavorable research or reports about our business, this may have a negative impact on the market price of our common stock.
  • The board of directors of KAYS has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stockholders and with the ability to adversely affect common stockholder voting power and rights upon liquidation.
  • The ability of our principal stockholders, including our CEO, to control our business may limit or eliminate minority stockholders’ ability to influence corporate affairs.
  • We do not expect to pay cash dividends in the foreseeable future.
  • The conversion of the 40 shares of KAYS’ outstanding Series D Preferred stock by the CEO and an unrelated third-party stockholder would result in the issuance of an additional 27,715,222 shares of KAYS’ common stock, (without taking into effect the conversion into shares of KAYS common stock of any or all outstanding convertible debt described in this prospectus). Accordingly, such market overhang could adversely impact the market price of the common stock.
  • Future sales of shares of KAYS common stock pursuant to Rule 144 under the Securities Act could adversely affect the market price of KAYS’s common stock.
  • Because we are not subject to compliance with rules requiring the adoption of certain corporate governance measures, our stockholders have limited protection against interested director transactions, conflicts of interest and similar matters.
  • You may experience dilution of your ownership interests because of the future issuance of additional shares of common stock.
  • We have agreed to indemnify our officers and directors and a Key Consultant against lawsuits to the fullest extent of the law.

Legal proceedings

From time-to-time KAYS may be party to various legal proceedings in the ordinary course of business. Please see paragraphs below for results of legal proceedings during 2024 and 2023.

Lawsuit from Law Offices of Ross Day

On September 9, 2022 the Company received notice from its Oregon Counsel that Day Law & Associates, P.C. (Attorney Ross Day is a former attorney for the Company) had filed suit in Washington County, Oregon seeking damages in the amount of $16,169.24 for unpaid legal fees, plus any costs, disbursements and attorney fees awarded.

On August 24, 2023 the Company and Day Law & Associates participated in an Arbitration in an attempt to resolve the Matter without Litigation, and on October 11, 2023 the Arbitrator ruled in favor of the Company and awarded the Company $3,000 in legal Fees and $781 in Costs. However, the Company subsequently agreed to waive the Award in consideration of Day Law dropping the matter.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
    SEC EDGAROther events
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events